Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

MacroGenics to Participate in Upcoming Investor Conferences

By GlobeNewswire

ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the following investor conferences in November:

  • Stifel 2026 Healthcare Conference (New York, NY). MacroGenics’ President and CEO, Eric Risser, will participate in a fireside chat on Wednesday, November 11, at 10:00 am ET. MacroGenics’ management will also participate in one-on-one meetings.
  • 9th Annual Evercore Healthcare Conference (Coral Gables, FL). Mr. Risser will participate in a fireside chat on Monday, November 30, at 3:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of these presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of the webcasts on its website for 30 days.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.


Contacts:Jim Karrels, Senior Vice President, CFO1-301-251-5172info@macrogenics.com Argot Partners1-212-600-1902macrogenics@argotpartners.com

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.